Biotech/Healthcare The misfortunes of the major pharmas dominate this sector as problems with new d...
Biotech/Healthcare The misfortunes of the major pharmas dominate this sector as problems with new drugs and patent expiry, particularly in 2006, hinder performance. AstraZeneca, whose pipeline and earnings potential are both attractively visible, is one of the few exceptions to this scenario which means most drug companies are trading at valuations below market average. Smaller biotech firms have, however, done well, although they could fall back from here. Dr Deane Donnigan, co-manager of Framlington Health, has been actively selling investments in this area. She says: "We have taken so...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes